Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Daily Feeds
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
89bio (ETNB)
NASDAQ:ETNB
ETNB Stock Chart & Stats
Day’s Range― - ―
52-Week Range$5.99 - $16.63
Previous Close$6.59
Volume1.55M
Average Volume (3M)3.01M
Market Cap
$1.59B
Enterprise Value$406.15M
Total Cash (Recent Filing)N/A
Total Debt (Recent Filing)N/A
Price to Earnings (P/E)―
Beta1.59
Next Earnings
Mar 19, 2025EPS Estimate
-0.75Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-2.91
Shares Outstanding145,745,240
10 Day Avg. Volume1,392,616
30 Day Avg. Volume3,012,012
Standard Deviation0.25
R-Squared0.05
Alpha0.00122
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)N/A
Price to Cash Flow (P/CF)-2.10
P/FCF Ratio0.00
Enterprise Value/Market Cap0.26
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit-1.49K
Enterprise Value/Ebitda-1.45
Forecast
1Y Price Target
$28.80Price Target Upside162.77% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering5
---
Bulls Say, Bears Say
Bulls Say
Clinical DevelopmentThe Phase 3 ENTRUST study for pegozafermin in severe hypertriglyceridemia has completed enrollment and is seen as a high-probability success.
Financial Position89Bio Inc. reported an updated cash position of $440 million, indicating a strong financial status to support further development.
Bears Say
Clinical Trial RisksRisks to the investment thesis include potential clinical trial failures, regulatory approval challenges, and market competition.
---
Ownership Overview
15.05% Insiders
9.94% Mutual Funds
44.30% Other Institutional Investors
21.79% Public Companies and Individual Investors
Risk Analysis
Main Risk Category
Tech & InnovationRisks related to the company’s reliance on technology and ability to make innovative products
Website Traffic
Sorry, No Data AvailableThere is no website visitor data available for this stock.
---
ETNB FAQ
What was 89bio’s price range in the past 12 months?
89bio lowest stock price was $5.99 and its highest was $16.63 in the past 12 months.
What is 89bio’s market cap?
89bio’s market cap is $1.59B.
When is 89bio’s upcoming earnings report date?
89bio’s upcoming earnings report date is Mar 19, 2025 which is in 26 days.
How were 89bio’s earnings last quarter?
89bio released its earnings results on Nov 07, 2024. The company reported -$1.39 earnings per share for the quarter, missing the consensus estimate of -$0.624 by -$0.766.
Is 89bio overvalued?
According to Wall Street analysts 89bio’s price is currently Undervalued.
Does 89bio pay dividends?
89bio does not currently pay dividends.
What is 89bio’s EPS estimate?
89bio’s EPS estimate is -0.75.
How many shares outstanding does 89bio have?
89bio has 145,745,240 shares outstanding.
What happened to 89bio’s price movement after its last earnings report?
89bio reported an EPS of -$1.39 in its last earnings report, missing expectations of -$0.624. Following the earnings report the stock price went up 4.92%.
Which hedge fund is a major shareholder of 89bio?
Currently, no hedge funds are holding shares in ETNB
---
89bio Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$28.80 (162.77% Upside)
$28.80 (162.77% Upside)
Blogger Sentiment
Bullish
ETNB Sentiment 100%
Sector Average 70%
Sector Average 70%
Insider Transactions
Bought Shares
Worth $50.3M over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Positive
Last 7 Days ▼ 1.1%
Last 30 Days ▲ 28.3%
Last 30 Days ▲ 28.3%
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Positive
20 days / 200 days
Momentum
10.81%
12-Months-Change
Fundamentals
Return on Equity
-73.31%
Trailing 12-Months
Asset Growth
-0.39%
Trailing 12-Months
Company Description
89bio
89bio, Inc. operates as a clinical-stage biopharmaceutical company. It focuses on the development and commercialization of innovative therapies for nonalcoholic steatohepatitis (NASH), liver and cardio-metabolic diseases. The company was founded on January 01, 2018 and is headquartered in San Francisco, CA.
---
ETNB Stock 12 Month Forecast
Average Price Target
$28.80
▲(162.77% Upside)
Technical Analysis
Madrigal Pharmaceuticals
―
Galectin Therapeutics
―
Viking Therapeutics
―
vTv Therapeutics
―
Akero Therapeutics
―
Best Analysts Covering ETNB
1 Year
1 Year Success Rate
14/23 ratings generated profit
1 Year Average Return
+82.51%
reiterated a buy rating 19 days ago
Copying Thomas Smith's trades and holding each position for 1 Year would result in 60.87% of your transactions generating a profit, with an average return of +82.51% per trade.
---